Luts & Greenleigh Group
ABBV icon

Luts & Greenleigh Group’s AbbVie ABBV Stock Holding History

Luts & Greenleigh Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.66M Buy
14,004
+150
+1% +$38.5K 2.67% 6
2026
Q2 		$3.49M Buy
13,854
+58
+0.4% +$12.5K 2.64% 6
2026
Q1 		$3M Sell
13,796
-58
-0.4% -$12.9K 2.38% 6
2025
Q4 		$3.17M Sell
13,854
-15
-0.1% -$3.42K 2.69% 6
2025
Q3 		$3.21M Sell
13,869
-48
-0.3% -$9.8K 2.88% 6
2025
Q2 		$2.58M Sell
13,917
-89
-0.6% -$16.5K 2.48% 6
2025
Q1 		$2.93M Buy
14,006
+222
+2% +$43.2K 2.92% 5
2024
Q4 		$2.45M Buy
13,784
+27
+0.2% +$4.96K 2.42% 6
2024
Q3 		$2.72M Buy
13,757
+131
+1% +$24.4K 2.61% 5
2024
Q2 		$2.34M Buy
+13,626
New +$2.26M 2.43% 6
2023
Q4 		$2.1M Sell
13,554
-7
-0.1% -$1.02K 2.65% 5
2023
Q3 		$2.02M Sell
13,561
-53
-0.4% -$7.78K 2.51% 5
2023
Q2 		$1.83M Sell
13,614
-88
-0.6% -$12.9K 2.26% 5
2023
Q1 		$2.18M Sell
13,702
-261
-2% -$39.9K 2.77% 6
2022
Q4 		$2.26M Buy
+13,963
New +$2.14M 2.86% 4

Other funds holding ABBV

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Luts & Greenleigh Group's ABBV Position: Q3 2026 in Review

Luts & Greenleigh Group increased its AbbVie (ABBV) stake by 1.1% in Q3 2026, buying an estimated $38.5K and bringing the position to 14,004 shares worth $3.66M. The position accounts for 2.67% of the portfolio, ranked #6.

Luts & Greenleigh Group first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Luts & Greenleigh Group held 14,004 shares of AbbVie worth $3.66M as of Q3 2026.
  • Luts & Greenleigh Group bought 150 AbbVie shares in Q3 2026, an estimated $38.5K.
  • AbbVie made up 2.67% of Luts & Greenleigh Group's portfolio in Q3 2026, its #6 holding.
  • Luts & Greenleigh Group first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Luts & Greenleigh Group's 13F filing for Q3 2026, filed 5 Nov 2026.